imidafenacin and Sleep-Wake-Disorders

We investigated the influence of nocturia and sleep disturbance on health-related quality of life(HRQOL) using the Medical Outcomes Study 8-item Short Form Health Survey (SF-8) in patients with nocturia. We also assessed the effect of therapeutic intervention by means of an anticholinergic agent on the results of the SF-8. One hundred and eighty-four patients who voided at least once per night were surveyed using the SF-8, Overactive Bladder Symptom Score (OABSS), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). These parameters were also evaluated before and after 12 weeks of imidafenacin treatment in 51 patients with OAB accompanied by nocturia. The SF-8 physical component summary score (PCS) showed a significant decrease as nighttime voiding frequency increased. The mental health component summary score was 47.1 and 47.6 (which were lower than the standard value of 50) in the group with a nighttime frequency of once and ≥3/night, respectively. The SF-8 PCS and 6 subscales were negatively associated with nighttime voiding frequency, while the PSQI global score was positively associated with it. Imidafenacin significantly improved the OABSS, PSQI, and ESS, as well as the SF-8 score. This is the first study using the SF-8 to show that nocturia and sleep disturbance have a major influence on comprehensive HRQOL and that the SF-8 can be used to monitor HRQOL in OAB patients receiving treatment for nocturia.

Topics: Aged; Aged, 80 and over; Cholinergic Antagonists; Female; Health Status; Humans; Imidazoles; Male; Middle Aged; Nocturia; Predictive Value of Tests; Quality of Life; Sleep; Sleep Wake Disorders; Surveys and Questionnaires; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics

The effect of imidafenacin for the treatment of over active bladder (OAB), in 100 patients with urgency, nocturia or sleep disorders was examined by an open-labeled, non-randomized,non-controlled study. Prior to administration and at 4 weeks after administration (0.1 or 0 2 mg/day, p. o,), symptoms and sleep disorders were assessed using the Over Active Bladder Symptom Score (OABSS) and the Athens Insomnia Scale (AIS), respectively. After administration, OABSS scores and AIS scales were improved significantly when compared to baseline values. The change of nocturia scores was correlated closely with that of AIS scales. Imidafenacin was effective in OAB patients with urgency and nocturia. In addition, imidafenacin secondarily mitigated sleep disorders significantly.

Topics: Aged; Cholinergic Antagonists; Female; Humans; Imidazoles; Male; Nocturia; Sleep Wake Disorders; Urinary Bladder, Overactive

To evaluate the efficacy of imidafenacin on nocturia and sleep disorder in patients with overactive bladder (OAB).. A prospective multicenter study of imidafenacin 0.1 mg twice daily for patients with OAB and nocturia was conducted. At baseline and at week 4 and 8, patients were assessed using the overactive bladder symptom score (OABSS), frequency volume charts (FVC) and the Pittsburgh Sleep Quality Index (PSQI).. Treatment with imidafenacin significantly improved OAB symptoms. Imidafenacin also improved PSQI, especially subjective sleep quality, sleep latency and daytime dysfunction. In FVC, the number of daytime voids and nighttime voids significantly decreased and average voided volume significantly increased after imidafenacin. Subanalysis of FVC based on the patients' age revealed that nocturnal polyuria was more often found in patients aged 75 years or over than in those aged under 75 years (79 vs. 55%, p < 0.05). Treatment with imidafenacin significantly reduced the nocturnal polyuria index only in patients aged 75 years or over.. Imidafenacin can improve nocturia and sleep disorder in patients with OAB. The efficacy of imidafenacin on nocturia is attributable to an increase in bladder capacity and a decrease in nocturnal urine volume. We conclude that imidafenacin is an effective and safe drug for nocturia in patients with OAB.

Topics: Aged; Aged, 80 and over; Female; Humans; Imidazoles; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Polyuria; Sleep; Sleep Wake Disorders; Time Factors; Urinary Bladder, Overactive; Urodynamics